Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant 20 mg once daily vs placebo for inhibition of coronary atherosclerosis progression assessed by IVUS in overweight patients with clustering risk factors
2004-003929-27Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis, Overweight and cardiac risk factors comparing Rimonabant 20 mg once daily with Placebo (2 arms). Started Jul 2005; status: completed.
02
Drugs
rimonabant
03
Conditions
coronary arteriosclerosisOverweightcardiac risk factors
Beyond the preview
Go deeper on 2004-003929-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003929-27.